Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

William Fantegrossi

TitleAssociate Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPharmacology & Toxicology, College of Medicine
DivisionPharmacology & Toxicology Ct Nervous
AddressB323B Biomedical Research I
325 S. Elm St.
Mail Slot # 638
Little Rock AR 72205
Phone501-686-8645
vCardDownload vCard

    Collapse Research Funds 
    Collapse research activities
    HHSF223201610079C     (FANTEGROSSI, WILLIAM)Sep 12, 2016 - Mar 15, 2019
    Food & Drug Administration
    In vivo pharmacological studies for abuse liability testing
    Role: Principal Investigator

    R01DA039143     (PRATHER, PAUL L)May 15, 2016 - Apr 30, 2021
    NIH/NIDA
    Synthetic Cannabinoid Toxicity: Role of Biotransformation
    Role: Co-Investigator

    R01DA039195     (OWENS, SAMUEL)Apr 15, 2015 - Aug 31, 2019
    NIH/Nat. Inst. on Drug Abuse
    Pharmacology and Therapy for MDPV and alpha-PVP Like Drugs of Abuse
    Role: Co-Investigator

    R01DA036600     (PETERSON, ERIC C)Jul 1, 2014 - Jun 30, 2018
    NIH/NIDA
    Antibody Gene Therapy for Methamphetamine Abuse
    Role: Co-Investigator

    T32DA022981     (KILTS, CLINTON D)Apr 1, 2007 - Jun 30, 2024
    NIH/NIDA
    Translational Training in Addiction
    Role: Co-Investigator

    R21DA020645     (FANTEGROSSI, WILLIAM E)Apr 1, 2006 - Mar 31, 2008
    NIH/NIDA
    Effects of self-administered MDMA on brain and behavior in rhesus monkeys
    Role: Principal Investigator

    F31DA005923     (FANTEGROSSI, WILLIAM E)Sep 1, 1999
    NIH/NIDA
    INTRAVENOUS SELF ADMINISTRATION OF MDMA
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Jones S, Yarbrough AL, Fantegrossi WE, Prather PL, Bush JM, Radominska-Pandya A, Fujiwara R. Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). Pharmacol Res Perspect. 2020 Feb; 8(1):e00561. PMID: 32003945.
      View in: PubMed
    2. Berquist MD, Leth-Petersen S, Kristensen JL, Fantegrossi WE. In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation. Drug Alcohol Depend. 2020 Jan 13; 208:107850. PMID: 31954950.
      View in: PubMed
    3. Gladden ME, Hung D, Bhandari NR, Franks AM, Russell L, White L, Fantegrossi WE, Payakachat N. Arkansas community's attitudes toward the regulation of medical cannabis and the pharmacist's involvement in Arkansas medical cannabis. J Am Pharm Assoc (2003). 2020 Jan - Feb; 60(1):235-243. PMID: 31831352.
      View in: PubMed
    4. Berquist MD, Leth-Petersen S, Kristensen JL, Fantegrossi WE. Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization. Psychopharmacology (Berl). 2019 Nov 15. PMID: 31729537.
      View in: PubMed
    5. Hyatt WS, Berquist MD, Chitre NM, Russell LN, Rice KC, Murnane KS, Fantegrossi WE. Repeated administration of synthetic cathinone 3,4-methylenedioxypyrovalerone persistently increases impulsive choice in rats. Behav Pharmacol. 2019 10; 30(7):555-565. PMID: 31211703.
      View in: PubMed
    6. Acheson A, Fantegrossi WE. Introduction to special issue: Therapeutic and abuse-related effects of cannabis and cannabinoids. Exp Clin Psychopharmacol. 2019 Aug; 27(4):299-300. PMID: 31355665.
      View in: PubMed
    7. Griffin BA, Caperton CO, Russell LN, Cabanlong CV, Wilson CD, Urquhart KR, Martins BS, Zita MD, Patton AL, Alund AW, Owens SM, Fantegrossi WE, Moran JH, Brents LK. In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. J Pharmacol Exp Ther. 2019 07; 370(1):9-17. PMID: 31028107.
      View in: PubMed
    8. Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica. 2019 Dec; 49(12):1388-1395. PMID: 30739533.
      View in: PubMed
    9. Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with ?9-Tetrahydrocannabinol and JWH-018. J Pharmacol Exp Ther. 2019 05; 369(2):259-269. PMID: 30833484.
      View in: PubMed
    10. Wilson CD, Tai S, Ewing L, Crane J, Lockhart T, Fujiwara R, Radominska-Pandya A, Fantegrossi WE. Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice. J Pharmacol Exp Ther. 2019 02; 368(2):146-156. PMID: 30420360.
      View in: PubMed
    11. Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A, Prather PL. Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to ?9-THC. Front Pharmacol. 2018; 9:1084. PMID: 30319418.
      View in: PubMed
    12. Tai S, Vasiljevik T, Sherwood AM, Eddington S, Wilson CD, Prisinzano TE, Fantegrossi WE. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Drug Alcohol Depend. 2018 11 01; 192:285-293. PMID: 30300803.
      View in: PubMed
    13. Yadlapalli JSK, Bommagani SB, Mahelona RD, Wan A, Gannon BM, Penthala NR, Dobretsov M, Crooks PA, Fantegrossi WE. Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-O-sulfate in rats: Drug discrimination and physical dependence. Pharmacol Res Perspect. 2018 07; 6(4):e00403. PMID: 29930811.
      View in: PubMed
    14. Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochem Biophys Res Commun. 2018 04 06; 498(3):597-602. PMID: 29522717.
      View in: PubMed
    15. Mu S, Fantegrossi WE, Rusch NJ. Cocaine-Responsive miRNA and Blood Pressure Elevation. Hypertension. 2018 04; 71(4):561-562. PMID: 29483229.
      View in: PubMed
    16. Fantegrossi WE, Wilson CD, Berquist MD. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev. 2018 Feb; 50(1):65-73. PMID: 29385930.
      View in: PubMed
    17. Berquist MD, Fantegrossi WE. Discriminative Stimulus Effects of Psychostimulants. Curr Top Behav Neurosci. 2018; 39:29-49. PMID: 28341944.
      View in: PubMed
    18. Gannon BM, Williamson A, Rice KC, Fantegrossi WE. Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice. Neuropharmacology. 2018 05 15; 134(Pt A):13-21. PMID: 28887185.
      View in: PubMed
    19. Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL. Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development. Pharmacol Res. 2017 Nov; 125(Pt B):161-177. PMID: 28838808.
      View in: PubMed
    20. Berquist MD, Hyatt WS, Bauer-Erickson J, Gannon BM, Norwood AP, Fantegrossi WE. Phencyclidine-like in vivo effects of methoxetamine in mice and rats. Neuropharmacology. 2018 05 15; 134(Pt A):158-166. PMID: 28830759.
      View in: PubMed
    21. Gannon BM, Russell LN, Modi MS, Rice KC, Fantegrossi WE. Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice. Drug Alcohol Depend. 2017 10 01; 179:408-415. PMID: 28866386.
      View in: PubMed
    22. Lantz SM, Rosas-Hernandez H, Cuevas E, Robinson B, Rice KC, Fantegrossi WE, Imam SZ, Paule MG, Ali SF. Monoaminergic toxicity induced by cathinone phthalimide: An in vitro study. Neurosci Lett. 2017 Aug 10; 655:76-81. PMID: 28684237.
      View in: PubMed
    23. Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic Pot: Not Your Grandfather's Marijuana. Trends Pharmacol Sci. 2017 03; 38(3):257-276. PMID: 28162792.
      View in: PubMed
    24. Tai S, Fantegrossi WE. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Curr Top Behav Neurosci. 2017; 32:249-262. PMID: 28012093.
      View in: PubMed
    25. Gannon BM, Fantegrossi WE. Cocaine-Like Discriminative Stimulus Effects of Mephedrone and Naphyrone in Mice. J Drug Alcohol Res. 2016; 5. PMID: 28424752.
      View in: PubMed
    26. Rosas-Hernandez H, Cuevas E, Lantz SM, Rice KC, Gannon BM, Fantegrossi WE, Gonzalez C, Paule MG, Ali SF. Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells. Neurosci Lett. 2016 08 26; 629:125-130. PMID: 27320055.
      View in: PubMed
    27. Farrell MS, McCorvy JD, Huang XP, Urban DJ, White KL, Giguere PM, Doak AK, Bernstein AI, Stout KA, Park SM, Rodriguiz RM, Gray BW, Hyatt WS, Norwood AP, Webster KA, Gannon BM, Miller GW, Porter JH, Shoichet BK, Fantegrossi WE, Wetsel WC, Roth BL. In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. PLoS One. 2016; 11(3):e0150602. PMID: 26963248.
      View in: PubMed
    28. Gannon BM, Williamson A, Suzuki M, Rice KC, Fantegrossi WE. Stereoselective Effects of Abused "Bath Salt" Constituent 3,4-Methylenedioxypyrovalerone in Mice: Drug Discrimination, Locomotor Activity, and Thermoregulation. J Pharmacol Exp Ther. 2016 Mar; 356(3):615-23. PMID: 26769917.
      View in: PubMed
    29. Baumann MH, Solis E, Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL. Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci. 2014 Nov 12; 34(46):15150-8. PMID: 25392483.
      View in: PubMed
    30. Smith DA, Bailey JM, Williams D, Fantegrossi WE. Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice. J Pharmacol Exp Ther. 2014 Dec; 351(3):485-91. PMID: 25271256.
      View in: PubMed
    31. Fantegrossi WE, Gray BW, Bailey JM, Smith DA, Hansen M, Kristensen JL. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice. Psychopharmacology (Berl). 2015 Mar; 232(6):1039-47. PMID: 25224567.
      View in: PubMed
    32. Gannon BM, Reichard EE, Fantegrossi WE. Psychostimulant Abuse and HIV Infection: cocaine, methamphetamine, and "bath salts" cathinone analogues. Curr Addict Rep. 2014 Sep 01; 1(3):237-242. PMID: 26413453.
      View in: PubMed
    33. Tai S, Fantegrossi WE. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. Curr Addict Rep. 2014 Jun 01; 1(2):129-136. PMID: 26413452.
      View in: PubMed
    34. Hyatt WS, Fantegrossi WE. ?9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice. Behav Pharmacol. 2014 Jun; 25(3):253-7. PMID: 24625557.
      View in: PubMed
    35. Norwood AP, Al-Chaer ED, Fantegrossi WE. Predisposing effects of neonatal visceral pain on abuse-related effects of morphine in adult male Sprague Dawley rats. Psychopharmacology (Berl). 2014 Nov; 231(22):4281-9. PMID: 24756764.
      View in: PubMed
    36. Patton AL, Seely KA, Pulla S, Rusch NJ, Moran CL, Fantegrossi WE, Knight LD, Marraffa JM, Kennedy PD, James LP, Endres GW, Moran JH. Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS. Anal Chem. 2014 Feb 04; 86(3):1760-6. PMID: 24354295.
      View in: PubMed
    37. Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013 Dec 10; 233(1-3):416-22. PMID: 24314548.
      View in: PubMed
    38. Fantegrossi WE, McCain KR, Moran JH, Hoffman RS. Not simply synthetic tetrahydrocannabinol. J Pediatr. 2013 Dec; 163(6):1797-8. PMID: 24128645.
      View in: PubMed
    39. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to ?(9)-THC: mechanism underlying greater toxicity? Life Sci. 2014 Feb 27; 97(1):45-54. PMID: 24084047.
      View in: PubMed
    40. Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, Fantegrossi WE, Kennedy PD, Dobrowolski P, Radominska-Pandya A, McCain KR, James LP, Endres GW, Moran JH. Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Anal Chem. 2013 Oct 01; 85(19):9390-9. PMID: 23987522.
      View in: PubMed
    41. Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE. Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J Pharmacol Exp Ther. 2013 Sep; 346(3):350-61. PMID: 23801678.
      View in: PubMed
    42. Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. J Med Chem. 2013 Jun 13; 56(11):4537-50. PMID: 23631463.
      View in: PubMed
    43. Fantegrossi WE, Brents LK, Hyatt WS, Kearney-Ramos T, Marshell R. (In Revision) In vivo effects of inhaled K2/“Spice” constituents JWH-018 and JWH-073 in mice. Psychopharmacology. 2013.
    44. Randolph MM, Gannon BM, Hyatt WS, Fantegrossi WE. (Under Review) Effects of laboratory housing conditions on thermoregulation and locomotor activity in mice. J of the Amer Assoc for Lab Animal Sci. 2013.
    45. Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Channell KB, Endres GW, Smith NH, McCain KR, James LP, Moran JH. (Under Review) Forensic investigation of K2, Spice, and "bath salt" commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013.
    46. Norwood AP, Al-Chaer ED, Fantegrossi WE. (Under Review) Neonatal visceral pain sensitizes subsequent abuse-related effects of morphine in rats. Psychopharmacology. 2013.
    47. Nichols DE, Fantegrossi WE. in Kuhar MJ and Madras BK (ed) The Effecs of Drug Abuse on the Human Nervous System. Update on Emerging Designer Drugs. 2013.
    48. Murnane KS, Martin JE, Jungst DN, Fantegrossi WE, Rice KC, Blough BE. (In Revision) Multiple serotonin receptors contribute to the acute toxic effects of the hallucinogen N,N-dipropyltryptamine in mice. Psychopharmacology. 2013.
    49. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. (Under Review) Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to ?9-THC: Mechanism underlying greater toxicity?. Life Sci. 2013.
    50. Fantegrossi WE, McCain KR, Moran JH, Hoffman RS. Not Simply Synthetic TNC. J Pediatrics. 2013.
    51. Fantegrossi WE, Xiao WR, Zimmerman SM. Novel technology for modulating locomotor activity as an operant response in the mouse: implications for neuroscience studies involving "exercise" in rodents. J Neurosci Methods. 2013 Jan 30; 212(2):338-43. PMID: 23164960.
      View in: PubMed
    52. Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC. In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology. 2013 Mar; 38(4):563-73. PMID: 23212455.
      View in: PubMed
    53. Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct; 63(5):905-15. PMID: 22771770.
      View in: PubMed
    54. Murnane KS, Perrine SA, Finton BJ, Galloway MP, Howell LL, Fantegrossi WE. Amphetamine derivatives impair passive avoidance performance and deplete central monoamines and their metabolites in mice: correlations between behavior and neurochemistry. Psychopharmacology (Berl). 2012; 220(3):495-508 [PMID: 21993877].
    55. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 2012 Apr 01; 83(7):952-61. PMID: 22266354.
      View in: PubMed
    56. Bisagno V, Fantegrossi WE, Urbano FJ. in Garcia-Rill E (ed) Translational Neuroscience: A Guide to a Successful Program. Translational Studies in Drug Abuse. 2012.
    57. Murnane KS, Perrine SA, Finton BJ, Galloway MP, Howell LL, Fantegrossi WE. Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry. Psychopharmacology (Berl). 2012 Apr; 220(3):495-508. PMID: 21993877.
      View in: PubMed
    58. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011; 6(7):e21917. PMID: 21755008.
      View in: PubMed
    59. Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem. 2011 Jun 01; 83(11):4228-36. PMID: 21506519.
      View in: PubMed
    60. Matsumoto RR, Li SM, Katz JL, Fantegrossi WE, Coop A. Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine. Drug Alcohol Depend. 2011 Oct 01; 118(1):40-7. PMID: 21420799.
      View in: PubMed
    61. Nichols D.E., And Fantegrossi W. E;. In Kuhar MJ and Madras BK (eds) The Effects of Drug Abuse on the Human Nervous System. Emerging Designer Drugs. 2011.
    62. Fantegrossi WE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC, Woods JH. Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther. 2010 Dec; 335(3):728-34. PMID: 20858706.
      View in: PubMed
    63. Murnane KS, Fantegrossi WE, Godrey JR, Banks ML, Howell LL. Endocrine and neurochemical effects of MDMA and its stereoisomers in rhesus monkeys. J Pharmacol Exp Ther. 2010; 334(2):642-650 [PMID: 20466795].
    64. McClung J, Fantegrossi W, Howell LL. Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys. Psychopharmacology (Berl). 2010 May; 210(1):75-83. PMID: 20309529.
      View in: PubMed
    65. Legendre O, Pecic S, Chaudhary S, Zimmerman SM, Fantegrossi WE, Harding WW. Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15; 20(2):628-31. PMID: 19963380.
      View in: PubMed
    66. Fantegrossi WE, Murai N, O'Mathuna B, Pizarro N, De La Torre R. Discriminative stimulus effects of MDMA and its enantiomers in mice: pharmacokinetic considerations. J Pharmacol Exp Ther. 2009; 329(3):1006-15 [PMID: 19279568].
    67. Fantegrossi WE, Bauzo RM, Manvich DM, Morales JC, Votaw JR, Goodman MM, Howell LL. Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates. Psychopharmacology (Berl). 2009 Aug; 205(2):337-47. PMID: 19421742.
      View in: PubMed
    68. Goeders JE, Murnane KS, Banks ML, Fantegrossi WE. Escalation of food-maintained responding and sensitivity to the locomotor stimulant effects of cocaine in mice. Pharmacol Biochem Behav. 2009 Jul; 93(1):67-74. PMID: 19376153.
      View in: PubMed
    69. Ko MC, Woods JH, Fantegrossi WE, Galuska CM, Wichmann J, Prinssen EP. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology. 2009 Aug; 34(9):2088-96. PMID: 19279568.
      View in: PubMed
    70. Fantegrossi WE, Murai N, Mathúna BO, Pizarro N, de la Torre R. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. J Pharmacol Exp Ther. 2009 Jun; 329(3):1006-15. PMID: 19276400.
      View in: PubMed
    71. Howell L.L, Fantegrossi WE. Methods of Behavior Analysis in Neuroscience. Intravenous Drug Self-Administration in Nonhuman Primates. 2008; 9.
    72. Fantegrossi WE. In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys. Exp Clin Psychopharmacol. 2008 Feb; 16(1):1-12. PMID: 18266547.
      View in: PubMed
    73. Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza R, Traynor JR, Woods JH. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience. 2008 Jan 24; 151(2):533-43. PMID: 18082974.
      View in: PubMed
    74. Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, Winter JC. Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav. 2008 Jan; 88(3):358-65. PMID: 17905422.
      View in: PubMed
    75. Weerts EM, Fantegrossi WE, Goodwin AK. The value of nonhuman primates in drug abuse research. Exp Clin Psychopharmacol. 2007 Aug; 15(4):309-27. PMID: 17696678.
      View in: PubMed
    76. Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 2008 Jan 01; 75(1):17-33. PMID: 17977517.
      View in: PubMed
    77. Kalechstein A.D, Fantegrossi W.E, Cowan R. L, And Mahoney J.J. Neuropsychology and Substance Abuse: State-of-the-Art and Future Directions. 2007.
    78. Kalechstein AD, De La Garza R, Mahoney JJ, Fantegrossi WE, Newton TF. MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl). 2007 Jan; 189(4):531-7. PMID: 17082969.
      View in: PubMed
    79. Fantegrossi WE. Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity? Psychopharmacology (Berl). 2007 Jan; 189(4):471-82. PMID: 16555062.
      View in: PubMed
    80. Fantegrossi WE, Kugle KM, Valdes LJ, Koreeda M, Woods JH. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol. 2005 Dec; 16(8):627-33. PMID: 16286814.
      View in: PubMed
    81. Fantegrossi WE, Kiessel CL, De la Garza R, Woods JH. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl). 2005 Sep; 181(3):529-36. PMID: 15983787.
      View in: PubMed
    82. Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl). 2005 Sep; 181(3):496-503. PMID: 15983786.
      View in: PubMed
    83. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte GA, Woods JH, Winger G. Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology. 2004 Jul; 29(7):1270-81. PMID: 15039771.
      View in: PubMed
    84. Fantegrossi WE, Kiessel CL, Leach PT, Van Martin C, Karabenick RL, Chen X, Ohizumi Y, Ullrich T, Rice KC, Woods JH. Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berl). 2004 May; 173(3-4):270-7. PMID: 14740148.
      View in: PubMed
    85. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl). 2003 Mar; 166(3):202-11. PMID: 12563544.
      View in: PubMed
    86. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl). 2002 Jun; 161(4):356-64. PMID: 12073162.
      View in: PubMed
    Fantegrossi's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _